The strong Phase 2b data materially de-risks volixibat's regulatory path in PSC. Monitor for the pre-NDA meeting outcome and any updates on the NDA submission timeline. The VANTAGE PBC readout in Q1 2027 adds a near-term pipeline catalyst.
MIRM drugs
MIRM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 4 $105.79entry
- T+1 · 7mo ago +0.02%α −0.78% · $105.81
- T+5 · 6mo ago +0.36%α −2.58% · $106.17
- T+20 · 6mo ago −8.94%α −14.59% · $96.33
- T+60 · 4mo ago +1.68%α −0.17% · $107.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mirum Pharmaceuticals announced positive Phase 2b results for volixibat in PSC, meeting the primary endpoint with high statistical significance (p<0.0001) and a robust placebo-adjusted improvement in pruritus. The company plans a pre-NDA meeting with the FDA in summer 2026 and an NDA submission in H2 2026, positioning volixibat as a potential first treatment for cholestatic pruritus in PSC.
Key Facts
- Primary endpoint met in VISTAS Phase 2b study of volixibat in PSC (p<0.0001).
- Placebo-adjusted improvement of 1.64 points on Adult ItchRO scale.
- 55.6% of volixibat patients achieved 2-point reduction vs 26.3% for placebo (p=0.0019).
- Pre-NDA meeting with FDA scheduled for summer 2026; NDA submission planned H2 2026.
- Safety profile consistent with IBAT inhibition; GI and liver enzyme elevations observed.
- Topline data from VANTAGE Phase 2b study in PBC expected Q1 2027.
Financial Impact
No financial figures reported; positive Phase 2b data supports regulatory advancement and potential to address an unmet medical need.
Risk Factors
- Safety signals including GI adverse events and liver enzyme elevations may raise regulatory concerns.
- NDA submission and FDA approval are not guaranteed; additional trials or data may be required.
- Competition from other therapies in development for PSC-related pruritus.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202609 |
| Document: 0001193125-26-202609-index-headers.html | 0001193125-26-202609 |
| Document: 0001193125-26-202609-index.html | 0001193125-26-202609 |
| Document: 0001193125-26-202609.txt | 0001193125-26-202609 |
Track record
27 reports on MIRM
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers